Q3 FY26 results: PAT up 18% YoY, EBITDA margins expand to 38.7%
CAPLIPOINT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved in line with Nifty Smallcap 250 and 0.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Caplin Point Labs reported Q3 FY26 consolidated revenue from operations of Rs 542.8 crores, up 10.1% YoY. Total revenue rose 9.9% to Rs 576.5 crores. EBITDA grew 15.3% to Rs 223.4 crores with margins expanding to 38.7% from 36.9%. PAT increased 18.4% to Rs 165.9 crores. For 9M FY26, total revenue up 11.2% to Rs 1,674 crores, PAT up 20.5% to Rs 477 crores. US market revenue grew 25% YoY. Free cash reserves at Rs 1,381 crores. Company remains net cash positive with Rs 2,459 crores liquid assets.
Strong broad-based growth with margin expansion and robust cash position. Net cash positive with healthy product pipeline. Positive for investors.